Key result
SGLT2i and GLP-1RA complement traditional antihypertensives to lower blood pressure in T2D.
Why the study?
Management strategies and appropriate blood pressure targets in individuals with type 2 diabetes and hypertension remain under discussion despite recognized residual cardiovascular risk.
Newer hypoglycemic agents such as SGLT2 inhibitors and GLP-1 receptor agonists offer complementary blood pressure reduction and cardiovascular risk benefits in patients with type 2 diabetes and hypertension.
Answers are grounded in this paper and cite their sources.
Optimal BP target in T2DM remains uncertain; leaves open need for definitive RCTs before practice change.
The presence of hypertension in individuals with type 2 diabetes augments the risk for cardiovascular morbidity and mortality. In this regard, data support that management of hypertension in this high-risk population is a critical risk reduction strategy. In recent years, a number of work groups have redefined hypertension, management strategies, and targets. In this context, there is still considerable discussion on an appropriate target for blood pressure in the diabetic population. However, despite this discussion on target blood pressure, it is widely recognized that there is considerable residual risk for heightened cardiovascular events in the hypertensive, diabetic population despite widespread awareness and treatment. There has been increasing interest in management strategies for blood pressure reduction in this high-risk population that complement traditional antihypertensive agents. Large-scale clinical trials have shown that hypoglycemic agents can complement blood pressure reduction and have a favorable effect on cardiovascular outcomes such as the sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. In the diabetic population, consideration should be given to the blood pressure lowering effects of the newer hypoglycemic agents when working toward additional glycemic control in patients with hypertension.
No takes yet. Share an insight, caveat, or question.
Khangura et al. (2018) conducted a review in Type 2 diabetes and hypertension. Hypoglycemic agents (SGLT2 inhibitors and GLP-1 receptor agonists) was evaluated. Newer hypoglycemic agents, such as SGLT2 inhibitors and GLP-1 receptor agonists, can complement traditional antihypertensive agents for blood pressure reduction in patients with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: